Europroteome 's strength in combining laboratory findings with clinical evidence is particularly suitable for a successful development work. However, in order to develop this discovery so that it can benefit the patient, we are dependent on collaborating with a business enterprise. This protein family has a significant effect on the development of malignant cells. Gunter Fischer, Managing Director of the Max-Planck Research Unit in Halle and scientific member of the Max-Planck-Society, added: "With the funds available to our Institute, we have been able to make some surprising discoveries about a protein family that is highly interesting from a pharmacological point of view. Brigth Crane Tai Chi Schule, Zürich Badi Oel / Badertscher Handels- u. On the basis of this, we can transfer the leading scientific position of the Max-Planck Research Unit into a promising pharmaceutical development program." 052 2022740 StadthausstraWinterthur, Zürich Seminarveranstalter : Top-Unternehmen. The collaboration is an outstanding evidence of the effectiveness of our company's Clinical Cancer Network and demonstrates the scientific and commercial potential that lies in the interaction between academia and biotech companies. During a later work stage, this active agent is to undergo pre-clinical followed by clinical testing.Īccording to Ulrich Traugott, MD, PhD, CEO of Europroteome AG: "The collaboration with the Max-Planck Unit in Halle will give Europroteome access to an extremely interesting class of proteins and will provide a starting point for a specific cancer therapy. These data form the starting point for producing an optimised active agent. The company was founded in 1998 and is based in Hennigsdorf, Germany. These substances are now being investigated for their effect on both healthy and diseased cells. Europroteome AG develops diagnostic, immunological, and prognostic tools as well as patient-specific therapies for human epithelial cancers. In an initial stage of the project, a number of natural substances (compounds) have been identified that can switch off the unwanted protein function and thus restrict the viability of cancer cells.
For the first time - by switching off this function - it is now possible to inhibit the ability of cancer cells to adapt - and thus to fight tumour development. This unwanted protein function enables the tumour to survive in situations favourable to the programmed cell death of cells (so-called apoptosis) experiencing uncontrolled growth. Latest findings have revealed that a protein family that has for a long time been associated with the viability of cancer cells and tumours has a hitherto unknown physiological function. The project is based on research results obtained by the "Max-Planck Research Unit for Enzymology of Protein Folding" in Halle/Saale. Project work is to commence in April 2004. Europroteome AG announces that it has been awarded a research grant as part of the BMBF's new BioChancePlus programme. Because of a conservative clinical culture and a skittish venture community, medical-device company creation has lagged in Europe.
0 kommentar(er)
